Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe-Reference-Cited by-同舟云学术

Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe

Published:2024-08-14 Issue: Volume: Page:1-12
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Diez-Campelo Maria¹^ORCID,Yucel Aylin²,Goyal Ravi K³^ORCID,Parikh Rohan C³^ORCID,Esterberg Elizabeth³^ORCID,Jimenez Maria³^ORCID,Sluga-O'Callaghan Martina⁴^ORCID,Miteva Dimana⁵,Xiao Hong²^ORCID,Germing Ulrich⁶

Affiliation:

1. Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain

2. Bristol Myers Squibb, Princeton,NJ 08540, USA

3. RTI Health Solutions, Research Triangle Park, NC 27709, USA

4. RTI Health Solutions, 69009 Lyon, France

5. Celgene International Sàrl, a Bristol-Myers Squibb Company, 2017 Boudry, Switzerland

6. Department of Haematology, Oncology, and Clinical Immunology, University Hospital of Dusseldorf, 40225 Dusseldorf, Germany

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2379228

Reference20 articles.

1. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it

2. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

3. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

4. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

5. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study